Idibell

Business Services · Spain · 201-500 Employees

View Company Info for Free

Overview

Headquarters

Av. Granvia De L'hospitalet 199 2A Plant...

Phone Number

+34 932607775

Revenue

$60.2 Million

Industry

Business Services Healthcare Services Research & Development Medical Laboratories & Imaging Centers
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About Idibell

IDIBELL is a biomedical research institute focused on cancer, neurosciences, translational medicine, and regenerative medicine. The institute aims to improve health outcomes through innovative research and collaboration with various stakeholders. It serves researchers, healthcare professionals, and patients, striving to reduce diagnostic times and enhance treatment options for rare diseases. IDIBELL is committed to continuous improvement and is accredited as a center dedicated to excellence in research.Explore more
Idibell's Social MediaPopular SearchesIdibellBellvitge Biomedical Research Institute IDIBELLIDIBELL - Bellvitge Biomedical Research InstituteIDIBELL Instituto de Investigacin Biomdica de Bell...SIC Code 87,873NAICS Code 54,541Show more

Is Idibell your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Idibell is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Idibell is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Idibell.

Idibell Tech Stack

A closer look at the technologies used by Idibell

Most Recent Scoops

Project
A front-line source in Artificial Intelligence has indicated that the organization is in the midst of initiatives related to artificial intelligence (AI) and machine learning operationalization. Idibell will be increasing investments and is considering the use of a contingent workforce to support these efforts. The organization is leveraging artificial intelligence (AI) tools to support drug design effort as part of these initiatives.
Spending/Investment, Contingent Workforce, Financial Planning, Machine Learning, Operating Systems
Project
A front-line source in Artificial Intelligence has indicated that the organization is in the midst of initiatives related to deep learning. Idibell is currently evaluating Keras and Torch. The organization will be increasing investments and is considering the use of a contingent workforce to support these efforts. The organization is leveraging artificial intelligence (AI) tools to support drug design effort as part of these initiatives.
Spending/Investment, Contingent Workforce, Financial Planning, Machine Learning
Project
A front-line source in Artificial Intelligence has indicated that the organization is in the midst of initiatives related to machine learning. Idibell is currently evaluating scikit-learn and Torch. The organization will be increasing investments and is considering the use of a contingent workforce to support these efforts. The organization is leveraging artificial intelligence (AI) tools to support drug design effort as part of these initiatives.
Spending/Investment, Contingent Workforce, Financial Planning, Machine Learning
Open Position
Open Position
See more scoops

Idibell News & Media

  • IDIBELL and Dexeus Mujer will study embryonic development by human embryo genome edition

    (IDIBELL-Bellvitge Biomedical Research Institute) The study aim is to determine the involvement of several genes in early stages of human embryonic development. To achieve this goal, Dr. Veiga's team will modify these genes by the genome editing technique CRISPR/Cas9, and they will study the development of the edited embryos. This is a unique and pioneering project in this field in Spain, which will provide very relevant information to understand the early development of the human
Read more news

Top Business Services Companies

Frequently Asked Questions Regarding Idibell

What is Idibell's official website?
Idibell's official website is idibell.cat
What is Idibell's Revenue?
Idibell's revenue is $60.2 Million
What is Idibell's SIC code?
Idibell's SIC: 87,873
What is Idibell's NAICS code?
Idibell's NAICS: 54,541
How many employees does Idibell have?
Idibell has 201-500 employees
What industry does Idibell belong to?
Idibell is in the industry of: Business Services, Healthcare Services, Research & Development
What technology does Idibell use?
Some of the popular technologies that Idibell uses are: WooCommerce, WordPress.org, reCAPTCHA, PHP
How do I contact Idibell?
Idibell contact info: Phone number: +34 932607775 Website: idibell.cat
What does Idibell do?

IDIBELL is a biomedical research institute focused on cancer, neurosciences, translational medicine, and regenerative medicine. The institute aims to improve health outcomes through innovative research and collaboration with various stakeholders. It serves researchers, healthcare professionals, and patients, striving to reduce diagnostic times and... enhance treatment options for rare diseases. IDIBELL is committed to continuous improvement and is accredited as a center dedicated to excellence in research.Read More

What are Idibell social media links?
Idibell Linkedin page Idibell Twitter page Idibell Facebook page
Is Idibell a public company?
Idibell is private company therefore does not currently have an official ticker symbol
See more information about Idibell

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.